Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice

被引：10

作者：

DeStefano, Christin B. ^{[2
,3
]}

Hourigan, Christopher S. ^{[1
]}

机构：

[1] NHLBI, Lab Myeloid Malignancies, NIH, 10 CRC,Room 5-5130,10 Ctr Dr, Bethesda, MD 20814 USA

[2] NIH, Lab Myeloid Malignancies, Bldg 10, Bethesda, MD 20892 USA

[3] MedStar Washington Canc Inst, Dept Hematol, Washington, DC USA

来源：

THERAPEUTIC ADVANCES IN HEMATOLOGY | 2018年 / 9卷 / 05期

基金：

美国国家卫生研究院;

关键词：

acute myeloid leukemia; novel agents; personalized therapy; ISOCITRATE DEHYDROGENASE MUTATIONS; GEMTUZUMAB OZOGAMICIN; OLDER PATIENTS; MYELODYSPLASTIC SYNDROME; INDUCTION CHEMOTHERAPY; INTENSIVE CHEMOTHERAPY; FLT3; DAUNORUBICIN; RESISTANCE; AML;

D O I：

10.1177/2040620718761778

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

While the past decade has seen a revolution in understanding of the genetic and molecular etiology of the disease, in clinical practice, initial therapy for acute myeloid leukemia (AML) patients has been a relatively straightforward choice between intensive combination cytotoxic induction therapy as used for decades or less-intensive hypomethylating therapy. The year 2017, however, witnessed US Food and Drug Administration approvals of midostaurin, enasidenib, gemtuzumab ozogamicin and CPX-351 for AML patients, with many other promising agents currently in clinical trials. This review discusses these options, highlights unanswered questions regarding optimal combinations and proposes some suggested approaches for the personalization of initial therapy for AML patients.

引用

页码：109 / 121

页数：13

共 54 条

[1] Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value [J].

Abbas, Saman ;

Lugthart, Sanne ;

Kavelaars, Francois G. ;

Schelen, Anita ;

Koenders, Jasper E. ;

Zeilemaker, Annelieke ;

van Putten, Wim J. L. ;

Rijneveld, Anita W. ;

Lowenberg, Bob ;

Valk, Peter J. M. .

BLOOD, 2010, 116 (12) :2122-2126

[2] Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform [J].

Al-Hussaini, Muneera ;

Rettig, Michael P. ;

Ritchey, Julie K. ;

Karpova, Darja ;

Uy, Geoffrey L. ;

Eissenberg, Linda G. ;

Gao, Feng ;

Eades, William C. ;

Bonvini, Ezio ;

Chichili, Gurunadh R. ;

Moore, Paul A. ;

Johnson, Syd ;

Collins, Lynne ;

DiPersio, John F. .

BLOOD, 2016, 127 (01) :122-131

[3] Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death [J].

Altman, Jessica K. ;

Rademaker, Alfred ;

Cull, Elizabeth ;

Weitner, Bing Bing ;

Ofran, Yishai ;

Rosenblat, Todd L. ;

Haidau, Augustin ;

Park, Jae H. ;

Ram, Sharona Lee ;

Orsini, James M., Jr. ;

Sandhu, Sonia ;

Catchatourian, Rosalind ;

Trifilio, Steven M. ;

Adel, Nelly G. ;

Frankfurt, Olga ;

Stein, Eytan M. ;

Mallios, George ;

Deblasio, Tony ;

Jurcic, Joseph G. ;

Nimer, Stephen ;

Peterson, LoAnn C. ;

Kwaan, Hau C. ;

Rowe, Jacob M. ;

Douer, Dan ;

Tallman, Martin S. .

LEUKEMIA RESEARCH, 2013, 37 (09) :1004-1009

[4] Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [J].

Amadori, Sergio ;

Suciu, Stefan ;

Selleslag, Dominik ;

Aversa, Franco ;

Gaidano, Gianluca ;

Musso, Maurizio ;

Annino, Luciana ;

Venditti, Adriano ;

Voso, Maria Teresa ;

Mazzone, Carla ;

Magro, Domenico ;

De Fabritiis, Paolo ;

Muus, Petra ;

Alimena, Giuliana ;

Mancini, Marco ;

Hagemeijer, Anne ;

Paoloni, Francesca ;

Vignetti, Marco ;

Fazi, Paola ;

Meert, Liv ;

Ramadan, Safaa Mahmoud ;

Willemze, Roel ;

de Witte, Theo ;

Baron, Frederic .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :972-+

[5]

[Anonymous], 2014, BLOOD, DOI DOI 10.1182/BLOOD.V124.21.389.389

[6] Gemtuzumab ozogamicin for acute myeloid leukemia [J].

Appelbaum, Frederick R. ;

Bernstein, Irwin D. .

BLOOD, 2017, 130 (22) :2373-2376

[7] Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? [J].

Araki, Daisuke ;

Wood, Brent L. ;

Othus, Megan ;

Radich, Jerald P. ;

Halpern, Anna B. ;

Zhou, Yi ;

Mielcarek, Marco ;

Estey, Elihu H. ;

Appelbaum, Frederick R. ;

Walter, Roland B. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04) :329-+

[8]

Bross PF, 2001, CLIN CANCER RES, V7, P1490

[9] Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis [J].

Buckley, Sarah A. ;

Wood, Brent L. ;

Othus, Megan ;

Hourigan, Christopher S. ;

Ustun, Celalettin ;

Linden, Michael A. ;

DeFor, Todd E. ;

Malagola, Michele ;

Anthias, Chloe ;

Valkova, Veronika ;

Kanakry, Christopher G. ;

Gruhn, Bernd ;

Buccisano, Francesco ;

Devine, Beth ;

Walter, Roland B. .

HAEMATOLOGICA, 2017, 102 (05) :865-873

[10] A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients [J].

Burnett, Alan K. ;

Russell, Nigel H. ;

Hills, Robert K. ;

Kell, Jonathan ;

Cavenagh, Jamie ;

Kjeldsen, Lars ;

McMullin, Mary-Frances ;

Cahalin, Paul ;

Dennis, Mike ;

Friis, Lone ;

Thomas, Ian F. ;

Milligan, Don ;

Clark, Richard E. .

BLOOD, 2015, 125 (25) :3878-3885

← 1 2 3 4 5 6 →